Description
Objective: Develop a non-invasive wearable device that can discretely detect biomarkers for and provide initial broad-spectrum treatment for pan-viral and pan-bacterial infections. If fielded for military use, it may require additional security measures. Description: The DHA Strategic Research Plan (SRP): Environmental Exposures (June 2024) lists two capability requirements under the “Assess” and “Treat” capability areas that align with this proposal: Environmental Detection and Health Risk Assessments under Assess and Environmental Exposures Treatment under Treat. In addition, the DHA SRP: Military Infectious Diseases (May 2024) lists three capability requirements under the “Prevent”, “Treat”, and “Enable” capability areas that align with this proposal: Prevention of Military Relevant Endemic and Emerging Infectious Diseases under Prevent, Treatment of Military Relevant Endemic and Emerging Infectious Diseases under Treat, and Core Competencies under Enable. The Department of the Air Force (DAF) is looking for an advanced, non-invasive (does not break the skin or physically enter the body) wearable device (i.e., flash/continuous glucose style monitoring) capable of qualitatively detecting all-viral and all-bacterial infections using discrete biomarkers for such infections: TRAIL, MxA, CD46, IP-10, PTX3, or other non-blood based biomarkers (saliva, sweat, etc.) for viral infections and CRP, PCT, IL-6, IL-8, CD35, CD55, CD64, pro-ADM, or other non-blood based biomarkers (saliva, sweat, etc.) for bacterial infections. The end goal is a wearable device that discretely detects viral and bacterial infections and renders initial, broad-spectrum anti-viral or anti-bacterial treatment(s) at austere operational environments where no immediate medical countermeasures and no other detection capabilities are available until casualties are evacuated to locations with more robust medical resources for additional and specific differentiation and treatment. At a higher echelon of care, medical personnel must be able to receive data from the device to find out what category of threats (viral or bacterial) has triggered a biomarker detection and what corresponding treatments have been rendered to the affected force before providing more advanced care. By continuously monitoring validated biomarkers, this device will empower warfighters to detect and respond to biological threats early, enhancing their survivability and operational effectiveness in high-threat theaters and mitigating risks to mission and force. This Air Force Medical Command initiative improves force health protection and ensures mission success. Dual-use functionality of this technology will focus on civilian healthcare systems. Keywords: Wearable device; biosensors; viruses and bacteria detection; biomarkers, drug delivery system; algorithms; monitoring; warfighters, deployers, medical countermeasures innovation CMMC Level: Level 1